within Pharmacolibrary.Drugs.ATC.J;

model J05AR06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.76,
    Cl             = 0.00016333333333333336,
    adminDuration  = 600,
    adminMass      = 1100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.075,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.020833333333333332,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AR06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose combination of three antiretroviral medications: emtricitabine (a nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor), and efavirenz (a non-nucleoside reverse transcriptase inhibitor). Used for the treatment of HIV-1 infection in adults and children and is currently approved for use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy HIV-negative adults receiving a single oral fixed-dose combination tablet (emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg, efavirenz 600 mg) under fasting conditions.</p><h4>References</h4><ol><li><p>Dando, TM, &amp; Wagstaff, AJ (2004). Emtricitabine/tenofovir disoproxil fumarate. <i>Drugs</i> 64(18) 2075–2084. DOI:<a href=\"https://doi.org/10.2165/00003495-200464180-00005\">10.2165/00003495-200464180-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15341498/\">https://pubmed.ncbi.nlm.nih.gov/15341498</a></p></li><li><p>Nirogi, R, et al., &amp; Mukkanti, K (2012). Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats. <i>Biopharmaceutics &amp; drug disposition</i> 33(5) 265–277. DOI:<a href=\"https://doi.org/10.1002/bdd.1794\">10.1002/bdd.1794</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22610784/\">https://pubmed.ncbi.nlm.nih.gov/22610784</a></p></li><li><p>Mathias, AA, et al., &amp; Kearney, BP (2007). Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. <i>Journal of acquired immune deficiency syndromes (1999)</i> 46(2) 167–173. DOI:<a href=\"https://doi.org/10.1097/QAI.0b013e3181427835\">10.1097/QAI.0b013e3181427835</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17667331/\">https://pubmed.ncbi.nlm.nih.gov/17667331</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AR06;
